Entrada Therapeutics advances ENTR — 601 — 44 Phase 1/2 DMD trial to 18 mg/kg Cohort 3 after DMC review
Entrada Therapeutics moved its ELEVATE-44-201 study into Cohort 3 at the top 18 mg/kg dose following a safety committee review. The committee reviewed available safety and drug-behavior data from eight Cohort 2 participants, supporting continued dose escalation. The trial is evaluating ENTR-601-44 in Duchenne muscular